Evidence map›Paper›PMID 12610520›Full record

ArticleBritish journal of cancer2003

Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2.

F De Paola, R Ridolfi, A Riccobon, E Flamini, F Barzanti, A M Granato, G L Mordenti, L Medri, P Vitali, D Amadori

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

F De PaolaDepartment of Medical Oncology, Pierantoni Hospital, AUSL-Forli, Italy.
R Ridolfi
A Riccobon
E Flamini
F Barzanti
A M Granato
G L Mordenti
L Medri
P Vitali
D Amadori
Ospedale G.B. Morgagni - L.Pierantoni · ITIstituto Oncologico Romagnolo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the effects of interleukin-2 (IL-2) exposure on T-cell signal transduction molecules and apoptosis markers in tumour-infiltrating lymphocytes (TIL) isolated from 20 melanoma and 16 colorectal carcinoma metastases and expanded in vitro for therapeutic reinfusion. Before IL-2 culture, TIL showed undetectable or very low levels of T-cell receptor (TCR) epsilon chain, p56(lck), Fas ligand (FasL) and Bax expression, while Bcl-2 values were elevated. Cancer cells were characterised by low or absent Fas and Bcl-2 and high Bax expression. Notably, they also expressed FasL. After 41-48 days of IL-2 culture, TCR epsilon chain and p56(lck) expression of TIL rose to median values of approximately 80 and 30% positive cells, respectively (P<0.001), FasL expression was detected in 45% cells from melanomas (P<0.001) and in 3% from colorectal carcinomas (P=0.09), and Bax-positive cells increased from 17.5 to 70% (P=0.005). Moreover, TCR zeta chain-positive cells were significantly increased from baseline (P=0.001), Bcl-2-positive cells dropped from 50 to 1% (P=0.007) and perforin content was high, while Fas expression was not significantly modified by IL-2 culture. In conclusion, our data suggest that the degree of immunosuppression in TIL from melanomas and colorectal carcinomas is very high, and the apoptosis markers' repertoire of cancer cells resembles that of immune-privileged tissue. Interleukin-2 culture appears to restore lymphocyte activation mechanisms, resulting in consistent FasL expression and perforin production.

Indexed as

AdultAgedAntibodies, MonoclonalAntineoplastic AgentsApoptosisbcl-2-Associated X ProteinCD3 ComplexColorectal NeoplasmsCytotoxicity, ImmunologicFas Ligand ProteinFemaleHumansImmunoenzyme TechniquesInterleukin-2In Vitro TechniquesLymphocyte ActivationAntibodies, Monoclonalantigen T cell receptor, zeta chainAntineoplastic AgentsBAX protein, humanbcl-2-Associated X ProteinCD3 ComplexFASLG protein, humanFas Ligand ProteinInterleukin-2Lymphocyte Specific Protein Tyrosine Kinase p56(lck)Membrane GlycoproteinsMembrane ProteinsPerforinPore Forming Cytotoxic ProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2Receptors, Antigen, T-Cell

Identifiers

PMID12610520
PMCPMC2377057
OpenAlexW2096860410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.